VivoSeq
Oncology

Fallopian Tube Cancer

130

Pipeline Programs↗

15

Active Trials↗

51

Companies Involved↗

Fallopian Tube Cancer is a highly competitive landscape with 130 programs across 51 companies. The most active players are AbbVie, OncoMed Pharmaceuticals, Inc., Kazia Therapeutics Limited. 4 therapies are approved with 23 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

6/100

Mech. Concentration

5/100

Completion Rate

78/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 1O

OncoMed Pharmaceuticals, Inc.

1 program

Phase 1K

Kazia Therapeutics Limited

1 program

Phase 1S

Sebela Pharmaceuticals Development LLC

1 program

Phase 1J

Javelin Pharmaceuticals

1 program

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical6

Bevacizumab

Bio-Thera Solutions

Filgrastim

Eastern Cooperative Oncology Group

Standard Chemotherapy

Roche

Oregovomab

Unither Pharmaceuticals

Huaier Granule

Qidong Gaitianli Medicines Co., Ltd

Phase 134

Alemtuzumab

Genzyme, a Sanofi Company

Peginterferon Alfa-2b

Merck & Co.

Olaparib

AstraZeneca

Itraconazole

Sebela Pharmaceuticals Development LLC

Melphalan

Apotex Inc.

Phase 263

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Regorafenib

Bayer

Irinotecan

Pfizer

Mifepristone

Danco

Phase 323

Topotecan Hydrochloride

Gynecologic Oncology Group

Rucaparib

Bristol-Myers Squibb

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carboplatin

Avyxa

Paclitaxel

Teva

Approved4

Tamoxifen

AstraZeneca

Binimetinib

Pfizer

Alvimopan

Merck & Co.

Tivozanib

AVEO Pharmaceuticals, Inc.

Analysis

Modality Breakdown

77%

Small molecule

98 of 128 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody1411%Protein / enzyme75%Vaccine54%Peptide22%Antibody–drug conjugate1<1%Cell therapy1<1%

Small molecule leads; the ring shows all 128 classified programs, each share of the total. Modality classified for 100% of 144 pipeline programs.

Analysis

Trial Status

148

clinical trials

Completed94 · 64%
Terminated19 · 13%
Unknown status12 · 8%
Active, not recruiting8 · 5%
Recruiting6 · 4%
Withdrawn6 · 4%
Other3 · 2%

Clinical Trials

Trial Activity

148 trials

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Recruiting·MMayo Clinic·Phase 2·NCT05465941·43 enrolled
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Recruiting·GGOG Foundation·Phase 3·NCT05659381·220 enrolled
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT04575935·580 enrolled
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06682988·110 enrolled
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06834672·450 enrolled
An Open-label, Fixed Sequence Phase I Study to Evaluate the Effect of Itraconazole (a Strong CYP3A Inhibitor) on the Pharmacokinetics of AZ14170132, the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335, in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07402915·24 enrolled
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03579316·96 enrolled
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT00565851·1,052 enrolled
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT01167712·692 enrolled
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02101775·124 enrolled
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT03017131·9 enrolled
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT03029403·47 enrolled
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting·—·Phase 2·NCT03113487·29 enrolled
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02595892·70 enrolled
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Not yet recruiting·HHebei Medical University Fourth Hospital·N/A·NCT06010667·60 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)